GETINGE Revenue 2016-2023 | GNGBY
GETINGE revenue from 2016 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| GETINGE Annual Revenue (Millions of US $) |
|
|---|---|
| 2023 | $3,001 |
| 2022 | $2,804 |
| 2021 | $3,154 |
| 2020 | $3,250 |
| 2019 | $2,810 |
| 2018 | $2,782 |
| 2017 | $2,639 |
| 2016 | $3,478 |
| 2015 | $3,586 |
| GETINGE Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2023-09-30 | $704 |
| 2023-06-30 | $682 |
| 2023-03-31 | $683 |
| 2022-12-31 | $805 |
| 2022-09-30 | $659 |
| 2022-06-30 | $678 |
| 2022-03-31 | $662 |
| 2021-12-31 | $906 |
| 2021-09-30 | $730 |
| 2021-06-30 | $783 |
| 2021-03-31 | $735 |
| 2020-12-31 | $1,005 |
| 2020-09-30 | $900 |
| 2020-06-30 | $721 |
| 2020-03-31 | $625 |
| 2019-12-31 | $888 |
| 2019-09-30 | $651 |
| 2019-06-30 | $665 |
| 2019-03-31 | $605 |
| 2018-12-31 | $884 |
| 2018-09-30 | $635 |
| 2018-06-30 | $662 |
| 2018-03-31 | $601 |
| 2017-12-31 | $245 |
| 2017-09-30 | $824 |
| 2017-06-30 | $823 |
| 2017-03-31 | $747 |
| 2016-12-31 | $1,066 |
| 2016-09-30 | $813 |
| 2016-06-30 | $844 |
| 2016-03-31 | $755 |
| 2015-12-31 | $1,107 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.000B | $3.000B |
| Getinge AB develops, manufactures and sells products and services for operating rooms, intensive-care units, hospital wards, sterilization departments, elderly care for life science companies and institutions. The company's operating segments consists of Medical Systems, Extended Care and Infection Control. It operates primarily in the United Kingdom, France, the United States and Australia. Getinge AB is headquartered in Gothenburg, Sweden. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $122.161B | 15.33 |
| Cencora (COR) | United States | $44.832B | 17.48 |
| DiDi Global (DIDIY) | China | $24.983B | 0.00 |
| ICON (ICLR) | Ireland | $24.837B | 23.45 |
| Avantor (AVTR) | United States | $16.520B | 24.32 |
| Viatris (VTRS) | United States | $13.812B | 3.97 |
| CochLear (CHEOY) | Australia | $13.622B | 0.00 |
| Revvity (RVTY) | United States | $12.486B | 21.88 |
| Medpace Holdings (MEDP) | United States | $12.117B | 39.86 |
| Charles River Laboratories (CRL) | United States | $11.842B | 21.59 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.592B | 0.00 |
| Natera (NTRA) | United States | $11.317B | 0.00 |
| Solventum (SOLV) | United States | $11.238B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| HealthEquity (HQY) | United States | $6.843B | 51.12 |
| Organon (OGN) | United States | $5.015B | 4.76 |
| Bausch + Lomb (BLCO) | Canada | $4.870B | 19.52 |
| Doximity (DOCS) | United States | $4.537B | 33.78 |
| PACS (PACS) | United States | $3.752B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.178B | 29.41 |
| Sotera Health (SHC) | United States | $3.088B | 15.15 |
| Progyny (PGNY) | United States | $3.082B | 51.73 |
| Life Times (LTH) | United States | $2.779B | 29.44 |
| GoodRx Holdings (GDRX) | United States | $2.769B | 140.20 |
| Premier (PINC) | United States | $2.543B | 9.31 |
| AMN Healthcare Services Inc (AMN) | United States | $2.281B | 7.38 |
| Teladoc Health (TDOC) | United States | $2.203B | 0.00 |
| Agilon Health (AGL) | United States | $1.985B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.893B | 0.00 |
| NovoCure (NVCR) | Jersey | $1.527B | 0.00 |
| Agiliti (AGTI) | United States | $1.369B | 22.36 |
| Establishment Labs Holdings (ESTA) | $1.359B | 0.00 | |
| Alignment Healthcare (ALHC) | United States | $1.003B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.766B | 7.93 |
| Embecta (EMBC) | United States | $0.589B | 3.89 |
| InnovAge Holding (INNV) | United States | $0.554B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.511B | 0.00 |
| LifeMD (LFMD) | United States | $0.511B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.508B | 0.00 |
| Enhabit (EHAB) | United States | $0.501B | 45.41 |
| Auna S.A (AUNA) | Luxembourg | $0.500B | 0.00 |
| CareDx (CDNA) | United States | $0.480B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.466B | 0.00 |
| MultiPlan (MPLN) | United States | $0.429B | 0.00 |
| Beauty Health (SKIN) | United States | $0.399B | 0.00 |
| DocGo (DCGO) | United States | $0.366B | 58.50 |
| Sera Prognostics (SERA) | United States | $0.345B | 0.00 |
| ModivCare (MODV) | United States | $0.312B | 5.85 |
| Sharecare (SHCR) | United States | $0.269B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.265B | 0.00 |
| Biodesix (BDSX) | United States | $0.150B | 0.00 |
| So-Young (SY) | China | $0.128B | 43.00 |
| Oncology Institute (TOI) | United States | $0.086B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.072B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.054B | 0.00 |
| NeueHealth (NEUE) | United States | $0.050B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.038B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.037B | 0.00 |
| Nutex Health (NUTX) | United States | $0.032B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
| OncoCyte (OCX) | United States | $0.023B | 0.00 |
| DermTech (DMTK) | United States | $0.022B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.014B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| OpGen (OPGN) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.005B | 0.00 |
| Assure Holdings (IONM) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |